A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
暂无分享,去创建一个
J. Armitage | V. Diehl | T. Lister | R. Fisher | D. Longo | H. Holte | S. Horning | D. Crowther | P. Gobbi | D. Hasenclever | F. Mandelli | J. Glick | M. Björkholm | B. Glimelius | A. Polliack | L. Specht | J. Sweetenham | S. Proctor | G. Canellos | H. Eghbali | P. Carde | E. Brusamolino | D. Assouline | G. V. Hudson | Volker Diehl | V. Diehl | David Cunningham | Christophe Ferm
[1] K. Maclennan,et al. Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 30). , 1987, Clinical radiology.
[2] D. Deakin,et al. Factors affecting remission and survival in patients with advanced hodgkin's disease treated with MVPP , 1986, Hematological oncology.
[3] M. Pfreundschuh,et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease , 1995 .
[4] V. Diehl,et al. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Rossi,et al. HODGKIN'S DISEASE PROGNOSIS: A DIRECTLY PREDICTIVE EQUATION , 1988, The Lancet.
[6] P. Donnan,et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1991, European journal of cancer.
[7] B. Glimelius,et al. Treatment of Hodgkin's disease: the Swedish National Care Programme experience. , 1996, Leukemia & lymphoma.
[8] G. Mead,et al. PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Horning,et al. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] F. Berger,et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] L. Specht,et al. Prognostic factors in Hodgkin's disease. , 1996, Cancer treatment reviews.
[12] K. Maclennan,et al. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] D. Reece,et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.
[14] A. Horwich,et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Straus. High-risk Hodgkin's disease prognostic factors. , 1995, Leukemia & lymphoma.
[16] C. Gisselbrecht,et al. Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index. , 1995, Leukemia & lymphoma.
[17] M. Federico,et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. , 1996, Leukemia & lymphoma.
[18] M. Federico,et al. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial. , 1996, Leukemia.
[19] V. Diehl,et al. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] P. Gobbi,et al. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Ester Orlandi,et al. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] K. Maclennan,et al. The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21). , 1983, Clinical radiology.
[23] N. Nissen,et al. Prognostic factors in Hodgkin's disease stage IV , 1988, European journal of haematology.
[24] K. Maclennan,et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Diehl,et al. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. , 1995, Journal of Clinical Oncology.
[26] J. Radford,et al. An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] V. Diehl,et al. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] N. Nissen,et al. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden , 1988, European journal of haematology.
[29] V. Diehl,et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] J. Radford,et al. Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. , 1997, British Journal of Cancer.
[31] H. Stein,et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. , 1990 .
[32] V. Diehl,et al. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). , 1995, Leukemia & lymphoma.
[33] S. Horning,et al. Original article: The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease , 1992 .
[34] A. Oza,et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Gobbi,et al. Serum albumin in Hodgkin's disease , 1985, Cancer.
[36] P. Carde. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? , 1995, Leukemia & lymphoma.
[37] P. Gobbi,et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). , 1994, Haematologica.
[38] H. Holte,et al. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. , 1996, Acta oncologica.
[39] É. Lepage,et al. Surgical restaging of advanced Hodgkin's disease after first line chemotherapy , 1991, European journal of haematology.
[40] F. Berger,et al. Prognosis of patients with advanced hodgkin's disease , 1997, Cancer.
[41] P. Mazza,et al. Multivariate analysis of Hodgkin's disease prognosis. Fitness and use of a directly predictive equation. , 1989, Haematologica.
[42] S. Proctor,et al. Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging. , 1993, Leukemia.
[43] E. Jaffe,et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Morra,et al. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease. , 1989, Haematologica.
[45] E. Jaffe,et al. Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] P. Gobbi,et al. Prognostic significance of serum albumin in Hodgkin's disease. , 1986, Haematologica.
[47] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.
[48] M. Tubiana,et al. Prognostic factors in 454 cases of Hodgkin's disease. , 1971, Cancer research.
[49] N. Schmitz,et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Donnan,et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1992, Leukemia & lymphoma.
[51] J. Lynch,et al. Mediastinal bulk in Hodgkin disease. Method of measurement versus prognosis. , 1991, Investigative radiology.
[52] A. Santoro,et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] M. Björkholm,et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] C. Gisselbrecht,et al. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. , 1993, International journal of radiation oncology, biology, physics.
[55] A. Hagenbeek,et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] B. Uziely,et al. Hodgkin's Lymphoma: Results of ABVD Chemotherapy in 40 Patients with Advanced or Bulky Disease. , 1990, Leukemia & lymphoma.
[57] R. Fisher,et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] D. Deakin,et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. , 1985, Clinical radiology.
[59] B. Clarkson,et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Radford,et al. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.